Pure Global AI
NCT06417892Not yet recruiting

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

A Randomized Controlled Study of 2nd-line Treatment of Advanced G/GEJ Adenocarcinoma With Fruquintinib and Albumin-paclitaxel in Combination With or Without PD-1 Antibody in Patients Who Have Failed Treatment With PD-1 Antibody
Cancer Institute and Hospital, Chinese Academy of Medical SciencesClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Gastric Cancer
Drug/Device/Intervention
PD-1inhibitor
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & enrollment
Phase
N/A
Start date
May 15, 2024
End date
Nov 30, 2026
Enrollment
60 participants
Primary outcome

PFS

Summary

To explore the efficacy and safety of fruquintinib and albumin-paclitaxel combined with or
 without PD-1 antibody in the second-line treatment of advanced gastric/gastroesophageal
 junction adenocarcinoma that failed to be treated by anti-PD-1 /PD-L1 regimen

ICD-10 classifications
Gastric ulcerMalignant neoplasm of stomachMalignant neoplasm: Body of stomachCarcinoma in situ: StomachMalignant neoplasm: Stomach, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06417892
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06417892 through Pure Global AI's free database. This phase not specified trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Not yet recruiting. The study focuses on Gastric Cancer. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.